Press releases

TAXUS IV study demonstrates long-term safety and efficacy of TAXUS drug- eluting stent compared to bare-metal stent

TAXUS ATLAS studies also reinforce deliverability of TAXUS® Liberte® drug-eluting stent in long lesions and small vessels

One-year results from the SPIRIT III trial included an updated analysis of 1,002 patients with coronary artery disease

Data showed continued low incidences of adverse events and repeat revascularization through two years in complex patients

"The quarter represented a turn for us, with a number of positive developments," said Jim Tobin, President and Chief Executive Officer

Approximately 2,300 positions to be eliminated worldwide

Schedule of Company events for the Cardiovascular Research Foundation's (CRF) 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium

CE Mark for CONFIENT™ implantable cardioverter defibrillator (ICD) represents first Boston Scientific-branded cardiac rhythm management device to treat sudden cardiac death

A live webcast and replay of the October 19 conference call will be available

Data reflects the experience from the first 15,000 patients monitored wirelessly on the LATITUDE® Patient Management System

With the election of Mr. Elliott, the Boston Scientific Board increases to 15 members

Analysis of TAXUS II, IV, V and VI trials found paclitaxel-eluting stents had similar clinical outcomes in women and men, despite women’s higher risk profile

TAXUS® Stent shows no additional very late stent thrombosis

OLYMPIA launch phase results show positive outcomes in diabetic patients

Three Boston Scientific subsidiaries will pay a total of $16.75 million and admit no liability

Company plans to announce five-year results from the TAXUS II clinical trial

A live webcast and replay of the September 10 conference session will be available

Amendment to provide the Company additional financial flexibility as it implements initiatives designed to increase shareholder value

Transaction would advance company's plan to divest non-strategic assets and strengthen operating and financial performance

BSC to assume sole control of Pain Management business and emerging indications program, Advanced Bionics principals to purchase Auditory business and drug pump program

Endosurgery group to remain wholly owned by Boston Scientific

Business produces a range of products used to manage fluid and measure pressure during angiography and angioplasty procedures

"We made progress in a number of key areas during the quarter," said Jim Tobin, President and Chief Executive Officer

TAXUS PERSEUS clinical program to evaluate platinum enhanced drug-eluting stent

Successful implantation marks the beginning of the TAXUS PETAL I First Human Use (FHU) Trial

Claims associated with a series of product communications issued by Guidant Corporation in 2005 and 2006; Company acquired Guidant Corporation last year

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2007...

Hardware and software innovations offer new benefits to physicians and patients

Acquisition to bring innovative sensor and wireless communication technology, complementing Company's Cardiac Rhythm Management product line

Deal follows successful four-year exclusive distribution of Prolieve® Thermodilatation System

A live webcast and replay of the June 13 conference session will be available

Article in April 24 edition of JACC highlights shorter procedure time, lower bailout rate

Study seeks to confirm the safety and efficacy of systems in routine clinical practice

Longest drug-eluting stent approved for the management of patients with clinically challenging coronary artery disease

SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACE after one year

Study highlights importance of antiplatelet therapy compliance

Trial results report no new stent thrombosis after two years in high-risk patient population

Group supports call for limiting greenhouse gas emissions

Company anticipates broad range of clinical results on endoscopic technologies

Single-operator system allows unprecedented visual access to bile duct

Company to release broad range of clinical data on leading drug-eluting stent portfolio

More than 23,000 patients now enrolled in TAXUS OLYMPIA registry

New data provide support for minimally invasive treatment of atrial fibrillation (AF)

Data represents the industry's largest experience with wireless remote monitoring of implantable cardiac devices for one year

Reimbursement granted by National Health Insurance System

RENAISSANCE trial demonstrates durable results for Company's Express® SD Renal Stent in treating hypertensive patients with severe renal artery stenosis

Sam Leno will join the Company as Chief Financial Officer (CFO) and Executive Vice President of Finance and Information Systems

SYNTAX is the first trial to compare the results of drug-eluting stents with those of cardiac surgery in the most complex patient subsets

A live webcast and replay of the May 2 conference session will be available

"I am pleased we came in at the upper end of our ranges for sales and EPS for the quarter," said Jim Tobin, President and Chief Executive Officer

Product provides enhanced control for accessing desired vessel location

A live webcast and replay of the April 23 conference call will be available.

Company has resolved deficiencies in the warning letter issued by the U.S. Food and Drug Administration (FDA) to the Guidant Corporation

Company plans to launch the product after reimbursement approval is granted

Trial is designed to identify and investigate clinically relevant endpoints for evaluating the efficacy and durability of endovascular treatment of brain aneurysms

BTK CHILL study demonstrates high rate of limb protection at one year

TAXUS® Express2™ paclitaxel-eluting coronary stent system met its primary endpoint in the treatment of in-stent restenosis

Two-year review of TAXUS Stent safety data presented at ACC

Results reaffirm strength of Boston Scientific's dual drug-eluting stent program

Compliance program is the first of its kind in the medical device industry; is expected to launch in the United States later this year

Smallest Dual Chamber System offered in Japan provides enhanced therapies to patients at risk of sudden cardiac death

Company to host analyst meeting and symposium on drug-eluting stents

A live webcast and replay of the March 19 conference session will be available

IPO would involve Boston Scientific selling approximately 20 percent of the Endosurgery group and establishing a separately traded public company

Boston Scientific Corporation (NYSE: BSX) today announced several enhancements related to the governance of the company. "Boston Scientific is...

A live webcast and replay of the March 13 conference session will be available

Company looks forward to providing the Committee the information it has requested relating to TAXUS® paclitaxel-eluting coronary stents

Campaign spokesperson - a Formula race car driver, amputee, and chronic pain patient - to promote public awareness

Swedish registry further illustrates the strengths and weaknesses of so-called "real-world" registries when compared to prospective, randomized and actively controlled trials

Articles scheduled for publication in the March 8th edition confirm the safety and efficacy of TAXUS® Express2™ paclitaxel-eluting coronary stent system

DES patients have significantly lower rates of death, heart attack and re-intervention than BMS patients

Company supports the proposed expansion but also supports broader coverage

Company provides guidance for first quarter 2007December 31, 2006, as well as...

Company will webcast its conference call discussing financial results for the fourth quarter and the year ended December 31, 2006 on Thursday, February 1, at 8:30 a.m.

Boston Scientific Corporation (NYSE: BSX) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to expand its...

The live webcast and archived replay of the Thursday, February 1 call will be available

New U.S. shelf life is longer than any competing drug-eluting stent product

Court orders injunction and damages

U.K. Court of Appeal affirmed an earlier ruling to revoke the U.K. version of a European paclitaxel stent patent owned by Angiotech Pharmaceuticals, Inc.

Lower rates of re-intervention and major adverse events reported for the TAXUS Stent in study of diabetic patients

Boston Scientific only company to offer two distinct drug-eluting stent platforms

Boston Scientific Corporation (NYSE: BSX) today announced preliminary, unaudited net sales for its fourth quarter and full year ended December 31,...

Plan to increase innovation, productivity and competitiveness

Acquisition demonstrates Company's commitment to leadership in treating carotid artery disease

A live webcast and replay of the Tuesday, January 9th session will be available

Trial highlights the importance of appropriate pacing for patients at risk of sudden cardiac death

To date, no product complaints have been reported to Boston Scientific related to this issue, and there have been no reported injuries

Device now cleared for use in both carotid arteries and saphenous vein grafts

Data from 7000 TAXUS patients showed substantial benefits in keeping arteries open and avoiding repeat procedures

Data presented to a panel of experts assembled by the FDA in response to concerns about the incidence of late stent thrombosis in drug-eluting stents

A live webcast and replay of the November 29 session will be available

Becker will be responsible for managing the Company's global government affairs function, as well as its corporate public policy and political action committee

Lower re-intervention rates for the TAXUS Stent in diabetic patients

LATITUDE Patient Management is the first and only remote monitoring system to provide clinicians with direct device data integration capability into GE's Centricity Electronic Medical Record (EMR)

A replay of the webcast of today's analyst meeting will be archived and available in the Investor Relations section of the Company's website

Important and growing diabetic patient subset accounts for more than one-quarter of all coronary interventional procedures in the United States

Technology serves as second-generation platform for Company's market-leading TAXUS® paclitaxel-eluting coronary stent system

Company to acquire EndoTex

Innovative technology makes Precision™ spinal cord stimulator accessible to more patients

Brennan comes to the position with over 10 years’ experience at Boston Scientific; will be responsible for all aspects of investor relations